MedTrace Logo

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

NCT06754930 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-04-17

No results posted yet for this study

Summary

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

SHR-1826

SHR-1826 for injection.

DRUG

SHR-1316

SHR-1316 for injection.

DRUG

SHR-9839

SHR-9839 for injection.

DRUG

SHR-8068

SHR-8068 for injection.

DRUG

Ametinib mesylate

Ametinib mesylate.

DRUG

BP-102

BP-102 for injection.

DRUG

Carboplatin

Carboplatin for injection.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06754930 on ClinicalTrials.gov